News Archive
03/23/2022: New Hepatitis D Central Resource Available from Healio
02/22/2022: We Should Be Screening Now for HDV with Emerging Drug Therapies in Phase 3
02/17/2022: Four Questions with Professor Maria Buti: Understanding Hepatitis D
02/11/2022: New Hepatitis Delta Podcast Episode: Viral Hepatitis: On the Road to Elimination
02/04/2022: Patient Perspective: Living with HBV and HDV Coinfection in Pandemic Times
01/20/2022: Hepatitis D Changing Context Global Prevalence
01/04/2022: New Slideset Updated on Don't Delay with Delta: Best Practices and Calls to Action in HDV
12/21/2021: Bulevirtide Improves Quality of Life in Chronic HDV
12/20/2021: Medical Minutes Podcasts on HDV Epidemiology and Universal Screening
12/18/2021: Large Proportion of Undiagnosed Anti-HDV Positive Individuals Due to Lack of Testing
12/16/2021: UN Adopts Resolution on Rare Diseases
12/13/2021: Bulevirtide Shows Real-World Efficacy Versus HDV
12/03/2021: Should We Screen All Patients with Hepatitis B for Hepatitis Delta?
12/01/2021: Hepatitis Delta Presentations from the 2021 AASLD Liver Meeting Now Available
11/19/2021: Gilead Files BLA for Bulevirtide to Treat Chronic HDV Infection
07/28/2021: Hepatitis D: Neglected Disease in the Race to Eliminate Viral Hepatitis by 2030
07/12/2021: Significant Disruptions in the International Incidence of Hepatitis Delta Virus
06/25/2021: Gilead Preps Filing for Hepatitis D Therapy Hepcludex in US
04/01/2021: Hepatitis Delta Infection Among Persons with HIV in Europe
10/7/20: Risk Factors for Delta Hepatitis in a North American Cohort: Who Should Be Screened?
9/17/20: Hepcludex Launched in Germany, France, and Austria
8/5/20: Hepcludex Approved by European Commission
2/18/20: New Insights into Hepatitis B and Hepatitis Delta Virus Entry
1/2/20: Hepatitis Delta Has Higher Health Care Cost Burden Than Hepatitis B
12/26/19: REP2139 Demonstrates Functional Cure in Both HBV, HDV
11/12/19: Eiger Announces Phase 2 LIFT Study Results During AASLD 2019
11/1/19: MYR Pharmaceuticals to Present on Myrcludex B During AASLD 2019
11/1/19: FDA Guidance to Help with Hepatitis Delta Drug Development
8/20/19: Pegylated Interferon Lambda Receives FDA Breakthrough Therapy Designation
7/29/19: Russia Plans Production of Myrcludex B
4/13/19: MYR Announces Phase 2 Myrcludex B Trial Data at The International Liver Congress 2019
4/11/19: Eiger Announces Phase 2 LIMT Hepatitis Delta Study Progress at The International Liver Congress 2019
12/18/18: Eiger Announces PRIME Designation Granted by European Medicines Agency for Lonafarnib
12/17/18: Eiger Announces Breakthrough Therapy Designation Granted by FDA for Lonafarnib
9/28/18: Global Hepatitis Delta Rates Highest Among HBV Coinfected with Risky Behaviors
6/4/18: Digestive Disease Week: Hepatitis Delta: The 'Forgotten Virus' is Still Here
10/23/18: MYR Pharma Announces FDA Breakthrough Therapy Designation for Myrcludex B
9/5/17: Pegylated Interferon Lambda Receives FDA Orphan Drug Designation
7/27/17: Pegylated Interferon Lambda Receives FDA Fast Track Designation
5/25/17: MYR Pharma Announces Myrcludex B PRIME Designation by the EMA
12/22/14: Lonafarnib Recieves Orphan Drug Designation by FDA and EMA